Actinium Pharmaceuticals, Inc.
NYSE · CIK 0001388320 · Fiscal year end 1231
Latest reported period: Latest published period
Operating Income
$-5.9M
Net Income
$-5.5M
Eps Basic
-0.18
Recent financials
| Metric | Current | Prior | Change |
|---|---|---|---|
| Operating Income | $-5.9M | - | - |
| Net Income | $-5.5M | - | - |
| Eps Basic | -0.18 | - | - |
| Eps Diluted | -0.18 | - | - |
| Cash And Equivalents | $42.1M | - | - |
| Total Assets | $45.4M | - | - |
| Total Liabilities | $43.1M | - | - |
| Shareholders Equity | $2.3M | - | - |
| Operating Cash Flow | $-5.9M | - | - |
| Capital Expenditures | $2,000 | - | - |
Latest filings
| Form | Company | Filed | Accession |
|---|---|---|---|
| 10-Q | Actinium Pharmaceuticals, Inc. | 2026-05-08 | 0001213900-26-053980 |
| 10-K | Actinium Pharmaceuticals, Inc. | 2026-03-30 | 0001213900-26-036504 |
| 10-Q | Actinium Pharmaceuticals, Inc. | 2025-11-14 | 0001213900-25-110979 |
| 4 | Actinium Pharmaceuticals, Inc. | 2025-08-20 | 0001213900-25-079019 |
| 10-Q | Actinium Pharmaceuticals, Inc. | 2025-08-08 | 0001213900-25-073743 |